Open AccessBrief Report: Dipyridamole Decreases Gut Mucosal Regulatory T-Cell Frequencies Among People With HIV on Antiretroviral Therapy
Author(s) -
Christina Mallarino-Haeger,
Kaleab Z. Abebe,
Edwin K. Jackson,
Ashley Zyhowski,
Cynthia Klamar-Blain,
Joshua C. Cyktor,
Diane Comer,
Rhonda M. Brand,
Delbert G. Gillespie,
Kyle Holleran,
John W. Mellors,
Ian McGowan,
Sharon A. Riddler,
Bernard Macatangay
Publication year - 2020
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0000000000002488
Subject(s) - dipyridamole , antiretroviral therapy , human immunodeficiency virus (hiv) , medicine , immunology , virology , viral load
We had previously conducted a double-blind, randomized placebo-controlled, partial cross-over trial showing that 12 weeks of dipyridamole decreased CD8 T-cell activation among treated HIV(+) individuals by increasing extracellular adenosine levels.